The stability and degradation pathway of recombinant human parathyroid hormone: deamidation of asparaginyl residue and peptide bond cleavage at aspartyl and asparaginyl residues
- PMID: 9453054
- DOI: 10.1023/a:1012115426306
The stability and degradation pathway of recombinant human parathyroid hormone: deamidation of asparaginyl residue and peptide bond cleavage at aspartyl and asparaginyl residues
Abstract
Purpose: The stability of recombinant human parathyroid hormone (rhPTH) was examined under acidic to alkaline conditions; its degradation pathways were elucidated from resultant products.
Methods: Degradation assay was performed in the pH range 2 to 10 at 40, 50 and 60 degrees C. The approximate molecular mass and pI values of the degradation products were estimated by electrophoresis. FAB-MS peptide mapping and amino acid composition analysis were used to determine these structures. The amount of each respective product was determined by HPLC.
Results: At pH2, eight degradation products were found: 1-30rhPTH, 1-74rhPTH, 1-71rhPTH, 1-56rhPTH, 1-45rhPTH, 46-84rhPTH, 31-84rhPTH and Asp76-rhPTH; these were mainly as a consequence of peptide bond cleavage of the amide bond of Asp. At pH9, five products were found: isoAsp16-rhPTH, Asp16-rhPTH, Asp57-rhPTH, Asp76-rhPTH, 17-84rhPTH; the main degradation pathway was deamidation of Asn via a cyclic imide intermediate. Degradation products resulting from cleavage at Asp were increased in proportion to the extent that pH was lowered below 5. As pH was increased above 5, so were products resulting from deamidation of Asn. Correspondingly, levels of intact rhPTH were at a peak at pH5.
Conclusions: Degradation of rhPTH under acidic conditions predominantly occurs by cleavage at Asp, whereas, above pH5, deamidation of Asn is the more prominent, rhPTH is most stable at pH5.
Similar articles
-
Peptide mapping of recombinant human parathyroid hormone by enzymatic digestion and subsequent fast-atom bombardment mass spectrometry.Rapid Commun Mass Spectrom. 1995;9(4):257-60. doi: 10.1002/rcm.1290090402. Rapid Commun Mass Spectrom. 1995. PMID: 7756699
-
Modes of Degradation and Impurity Characterization in rhPTH (1-34) during Stability Studies.PDA J Pharm Sci Technol. 2011 Jul-Aug;65(4):348-62. doi: 10.5731/pdajpst.2011.00745. PDA J Pharm Sci Technol. 2011. PMID: 22293522
-
Chemical pathways of peptide degradation. III. Effect of primary sequence on the pathways of deamidation of asparaginyl residues in hexapeptides.Pharm Res. 1990 Aug;7(8):787-93. doi: 10.1023/a:1015999012852. Pharm Res. 1990. PMID: 2235875
-
Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization.J Pharm Sci. 2006 Nov;95(11):2321-36. doi: 10.1002/jps.20740. J Pharm Sci. 2006. PMID: 16960822 Review.
-
Deamidation of asparagine and glutamine residues in proteins and peptides: structural determinants and analytical methodology.J Chromatogr B Biomed Appl. 1994 Dec 9;662(2):261-78. doi: 10.1016/0378-4347(94)00203-7. J Chromatogr B Biomed Appl. 1994. PMID: 7719481 Review.
Cited by
-
An Integrated Microcurrent Delivery System Facilitates Human Parathyroid Hormone Delivery for Enhancing Osteoanabolic Effect.Small Methods. 2025 Mar;9(3):e2401144. doi: 10.1002/smtd.202401144. Epub 2024 Oct 17. Small Methods. 2025. PMID: 39420694 Free PMC article.
-
A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood.J Vis Exp. 2016 Apr 28;(110):53959. doi: 10.3791/53959. J Vis Exp. 2016. PMID: 27166969 Free PMC article.
-
Demonstrated solid-state stability of parathyroid hormone PTH(1-34) coated on a novel transdermal microprojection delivery system.Pharm Res. 2009 Nov;26(11):2454-63. doi: 10.1007/s11095-009-9960-9. Pharm Res. 2009. PMID: 20183917
-
The RAPID method for blood processing yields new insight in plasma concentrations and molecular forms of circulating gut peptides.Endocrinology. 2009 Nov;150(11):5113-8. doi: 10.1210/en.2009-0697. Epub 2009 Oct 9. Endocrinology. 2009. PMID: 19819958 Free PMC article.
-
Discovery and Control of Succinimide Formation and Accumulation at Aspartic Acid Residues in The Complementarity-Determining Region of a Therapeutic Monoclonal Antibody.Pharm Res. 2023 Jun;40(6):1411-1423. doi: 10.1007/s11095-022-03462-0. Epub 2023 Jan 10. Pharm Res. 2023. PMID: 36627449
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous